94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Thoracic Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1505889
This article is part of the Research Topic Repurposed Drugs Targeting Cancer Signaling Pathways: Clinical Insights to Improve Oncologic Therapies Volume II View all 10 articles
Olaparib Monotherapy or Combination Therapy in Lung Cancer: an updated Systematic review and meta-analysis
Provisionally accepted
Sajjad Hajihosseini 1
Ehsan Emami 1
Amirali Zakavi 2 Parnia Jochin 3
Mehregan Shahrokhi 3 Sahar Khoshravesh 4 Mitra Goli 1 Mohaddeseh Belbasi 5
Gisou Erabi 6*
Niloofar Deravi 4*- 1 Tehran University of Medical Sciences, Tehran, Tehran, Iran
- 2 Ardabil University of Medical Sciences, Ardabil, Ardabil, Iran
- 3 Shiraz University of Medical Sciences, Shiraz, Fars, Iran
- 4 Shahid Beheshti University of Medical Sciences, Tehran, Tehran, Iran
- 5 Zanjan University of Medical Sciences, Zanjān, Iran
- 6 Urmia University of Medical Sciences, Urmia, Iran
Background and Aims : Impaired double strand DNA repair by homologous repair deficiency (HRD) leads to sensitivity to poly ADP ribose polymerase (PARP) inhibition. A subset of nonsmall cell lung cancers (NSCLCs) harbour impaired DNA double strand break repair. This study aims to investigate meta-analysis on the olaparib monotherapy or combination therapy in lung cancer.Methods: A comprehensive search was conducted in Pubmed, Scopus and Google Scholar data bases up to August 13, 2023 related articles were extracted title, abstract and full text of articles were screened. The quality included articles were assessing the data was extracted and hence analysis. Results: After screening 5208 articles, 9 were selected for final review based on relevance to the topic. Olaparib monotherapy increased progression free survival (PFS) level [ES= 7.76; 95% CI= 0.16 to 1.36; P=0.208]. Olaparib maintenance therapy increased PFS compared to placebo in platinum-sensitive NSCLC patients [ES= 0.9; 95% CI= 0.9 to 0.9]. Combination therapy with durvalumab and olaparib decreased PFS level compared to the olaparib group [ES=6.07; 95% confidence interval (95% CI) = 0.67 to 11.46; P=0.000]. Adding gefitinib to olaparib decreased PFS compared to olaparib only group, significantly (ES=3.39; 95% CI=-0.78 to 7.56; P=0.609).Conclusions : Our study demonstrated olaparib as monotherapy can increase the PFS of patients with lung cancer, but the combination of olaparib and gefitinib or the combination of olaparib plus durvalumab couldn't have a significant effect. According to the high heterogeneous rate of studies further large-scale randomized control trials are still required to progress association.
Keywords: olaparib, lung cancer, NSCLCs, gefitinib, durvalumab
Received: 03 Oct 2024; Accepted: 27 Feb 2025.
Copyright: © 2025 Hajihosseini, Emami, Zakavi, Jochin, Shahrokhi, Khoshravesh, Goli, Belbasi, Erabi and Deravi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Gisou Erabi, Urmia University of Medical Sciences, Urmia, 57147-83734, Iran
Niloofar Deravi, Shahid Beheshti University of Medical Sciences, Tehran, 198396-3113, Tehran, Iran
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.